Advertisement

Involvement of RhoA/ROCK Signaling in Aβ-Induced Chemotaxis, Cytotoxicity and Inflammatory Response of Microglial BV2 Cells

  • Xiaoxu Zhang
  • Piao Ye
  • Dandan Wang
  • Yunsheng Liu
  • Lan Cao
  • Yancong Wang
  • Yuxia XuEmail author
  • Cuiqing ZhuEmail author
Original Research

Abstract

Reactive microglia clustering around amyloid plaques in brain is a histopathological feature of Alzheimer’s disease (AD) and reflects the contribution of neuroinflammation in AD pathogenesis. β-Amyloid peptide (Aβ) has been shown to induce a range of microglial responses including chemotaxis, cytotoxicity and inflammation, but the underlying mechanism is poorly understood. Considering the fundamental role of RhoA/ROCK signaling in cell migration and its broad implication in AD and neuroinflammation, we hypothesized that RhoA/ROCK signaling might be involved in Aβ-induced microglial responses. From in vivo mouse models including APP/PS1 transgene and fibrillar Aβ stereotactic injection, we observed the elevated expression level of RhoA in reactive microglia. Through a series in vitro cell migration, cytotoxicity and biochemistry assays, we found that RhoA/ROCK signaling plays an essential role in Aβ-induced responses of microglial BV2 cells. Small molecular agents Fasudil and Y27632 showed prominent beneficial effects, which implies the therapeutic potential of RhoA/ROCK signaling inhibitors in AD treatment.

Keywords

Aβ Microglial BV2 cells RhoA/ROCK signaling Chemotactic migration Cytotoxicity Inflammatory response 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China, Grant Numbers 31671041 and 81471285.

Author Contributions

X.Z. performed all the experiments and wrote the manuscript. P.Y. contributed to part of immunofluorescence staining, cell culture and data analysis. D.W. contributed to write and review the manuscript. Y.W., L.C. and Y.L. contributed to some of in vitro analysis. C.Z. and Y.X. designed the study, analyzed data, and wrote the manuscript. All authors reviewed and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.

Supplementary material

10571_2019_668_MOESM1_ESM.tif (6.8 mb)
Supplementary material 1 (TIF 6996 KB)
10571_2019_668_MOESM2_ESM.tif (719 kb)
Supplementary material 2 (TIF 718 KB)
10571_2019_668_MOESM3_ESM.tif (677 kb)
Supplementary material 3 (TIF 676 KB)
10571_2019_668_MOESM4_ESM.tif (26 mb)
Supplementary material 4 (TIF 26633 KB)
10571_2019_668_MOESM5_ESM.docx (16 kb)
Supplementary material 5 (DOCX 15 KB)

References

  1. Alokam R, Singhal S, Srivathsav GS, Garigipati S, Puppala S, Sriram D, Perumal Y (2015) Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder. Mol Biosyst 11(2):607–617.  https://doi.org/10.1039/c4mb00570h CrossRefGoogle Scholar
  2. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin Anat 8(6):429–431.  https://doi.org/10.1002/ca.980080612 CrossRefGoogle Scholar
  3. Ark M, Ozveren E, Yazici G, Korkmaz B, Buyukafsar K, Arikan O, Kubat H, Songu-Mize E (2004) Effects of HA-1077 and Y-27632, two rho-kinase inhibitors, in the human umbilical artery. Cell Biochem Biophys 41(3):331–342.  https://doi.org/10.1385/CBB:41:3:331 CrossRefGoogle Scholar
  4. Chen TJ, Hung HS, Wang DC, Chen SS (2010) The protective effect of Rho-associated kinase inhibitor on aluminum-induced neurotoxicity in rat cortical neurons. Toxicol Sci 116(1):264–272.  https://doi.org/10.1093/toxsci/kfq114 CrossRefGoogle Scholar
  5. Chen J, Sun Z, Jin M, Tu Y, Wang S, Yang X, Chen Q, Zhang X, Han Y, Pi R (2017a) Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-kappaB pathway. J Neuroimmunol 305:108–114.  https://doi.org/10.1016/j.jneuroim.2017.02.010 CrossRefGoogle Scholar
  6. Chen J, Yin W, Tu Y, Wang S, Yang X, Chen Q, Zhang X, Han Y, Pi R (2017b) L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-kappaB inhibition and Nrf2 pathway activation. Eur J Pharmacol 806:1–9.  https://doi.org/10.1016/j.ejphar.2017.03.025 CrossRefGoogle Scholar
  7. Chodniewicz D, Klemke RL (2004) Guiding cell migration through directed extension and stabilization of pseudopodia. Exp Cell Res 301(1):31–37.  https://doi.org/10.1016/j.yexcr.2004.08.006 CrossRefGoogle Scholar
  8. Davis JB, McMurray HF, Schubert D (1992) The amyloid beta-protein of Alzheimer’s disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun 189(2):1096–1100CrossRefGoogle Scholar
  9. Ebrahimi T, Rust M, Kaiser SN, Slowik A, Beyer C, Koczulla AR, Schulz JB, Habib P, Bach JP (2018) Alpha1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid beta1-42-stimulated murine astrocytes. J Neuroinflamm 15(1):282.  https://doi.org/10.1186/s12974-018-1319-x CrossRefGoogle Scholar
  10. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4):432–438.  https://doi.org/10.1038/nm1555 CrossRefGoogle Scholar
  11. Fan Y, Xie L, Chung CY (2017) Signaling pathways controlling microglia chemotaxis. Mol Cells 40(3):163–168.  https://doi.org/10.14348/molcells.2017.0011 Google Scholar
  12. Fang Y, Wang J, Yao L, Li C, Wang J, Liu Y, Tao X, Sun H, Liao H (2018) The adhesion and migration of microglia to beta-amyloid (Abeta) is decreased with aging and inhibited by Nogo/NgR pathway. J Neuroinflamm 15(1):210.  https://doi.org/10.1186/s12974-018-1250-1 CrossRefGoogle Scholar
  13. Fu P, Tang R, Yu Z, Li C, Chen X, Xie M, Wang W, Luo X (2016) Rho-associated kinase inhibitors promote microglial uptake via the ERK signaling pathway. Neurosci Bull 32(1):83–91.  https://doi.org/10.1007/s12264-016-0013-1 CrossRefGoogle Scholar
  14. Fu W, Vukojevic V, Patel A, Soudy R, MacTavish D, Westaway D, Kaur K, Goncharuk V, Jhamandas J (2017) Role of microglial amylin receptors in mediating beta amyloid (Abeta)-induced inflammation. J Neuroinflamm 14(1):199.  https://doi.org/10.1186/s12974-017-0972-9 CrossRefGoogle Scholar
  15. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3(77):77sr71.  https://doi.org/10.1126/scitranslmed.3002369 CrossRefGoogle Scholar
  16. Huang WC, Yen FC, Shie FS, Pan CM, Shiao YJ, Yang CN, Huang FL, Sung YJ, Tsay HJ (2010) TGF-beta1 blockade of microglial chemotaxis toward Abeta aggregates involves SMAD signaling and down-regulation of CCL5. J Neuroinflamm 7:28.  https://doi.org/10.1186/1742-2094-7-28 CrossRefGoogle Scholar
  17. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 57(5):976–983Google Scholar
  18. Jeon YJ, Won HY, Moon MY, Choi WH, Chang CH, Lee JY, Kim J, Kim SC, Kim YS, Park JB (2008) Interaction of microglia and amyloid-beta through beta2-integrin is regulated by RhoA. Neuroreport 19(17):1661–1665.  https://doi.org/10.1097/WNR.0b013e3283140f10 CrossRefGoogle Scholar
  19. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL (2002) Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem 277(14):12479–12485.  https://doi.org/10.1074/jbc.M111147200 CrossRefGoogle Scholar
  20. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV (2014) In vitro cell migration and invasion assays. J Vis Exp.  https://doi.org/10.3791/51046 Google Scholar
  21. Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy PM, Oppenheim JJ, Wang JM (2001) Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 21(2):RC123CrossRefGoogle Scholar
  22. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V (2013) Inflammatory process in Alzheimer’s disease. Front Integr Neurosci 7:59.  https://doi.org/10.3389/fnint.2013.00059 CrossRefGoogle Scholar
  23. Moon MY, Kim HJ, Li Y, Kim JG, Jeon YJ, Won HY, Kim JS, Kwon HY, Choi IG, Ro E, Joe EH, Choe M, Kwon HJ, Kim HC, Kim YS, Park JB (2013) Involvement of small GTPase RhoA in the regulation of superoxide production in BV2 cells in response to fibrillar Abeta peptides. Cell Signal 25(9):1861–1869.  https://doi.org/10.1016/j.cellsig.2013.05.023 CrossRefGoogle Scholar
  24. Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol 88(4):594–604.  https://doi.org/10.1016/j.bcp.2014.01.008 CrossRefGoogle Scholar
  25. Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4(5):387–398.  https://doi.org/10.1038/nrd1719 CrossRefGoogle Scholar
  26. Park JC, Baik SH, Han SH, Cho HJ, Choi H, Kim HJ, Choi H, Lee W, Kim DK, Mook-Jung I (2017) Annexin A1 restores Abeta1-42 -induced blood–brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. Aging Cell 16(1):149–161.  https://doi.org/10.1111/acel.12530 CrossRefGoogle Scholar
  27. Raftopoulou M, Hall A (2004) Cell migration: Rho GTPases lead the way. Dev Biol 265(1):23–32CrossRefGoogle Scholar
  28. Ransohoff RM (2016) A polarizing question: do M1 and M2 microglia exist? Nat Neurosci 19(8):987–991.  https://doi.org/10.1038/nn.4338 CrossRefGoogle Scholar
  29. Scheiblich H, Bicker G (2017) Regulation of microglial phagocytosis by RhoA/ROCK-inhibiting drugs. Cell Mol Neurobiol 37(3):461–473.  https://doi.org/10.1007/s10571-016-0379-7 CrossRefGoogle Scholar
  30. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675CrossRefGoogle Scholar
  31. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8(6):595–608.  https://doi.org/10.15252/emmm.201606210 CrossRefGoogle Scholar
  32. Sellers KJ, Elliott C, Jackson J, Ghosh A, Ribe E, Rojo AI, Jarosz-Griffiths HH, Watson IA, Xia W, Semenov M, Morin P, Hooper NM, Porter R, Preston J, Al-Shawi R, Baillie G, Lovestone S, Cuadrado A, Harte M, Simons P, Srivastava DP, Killick R (2018) Amyloid beta synaptotoxicity is Wnt-PCP dependent and blocked by Fasudil. Alzheimers Dement 14(3):306–317.  https://doi.org/10.1016/j.jalz.2017.09.008 CrossRefGoogle Scholar
  33. Sheng JG, Mrak RE, Griffin WS (1997) Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol 94(1):1–5CrossRefGoogle Scholar
  34. Sindi S, Mangialasche F, Kivipelto M (2015) Advances in the prevention of Alzheimer’s disease. F1000Prime Rep 7:50.  https://doi.org/10.12703/P7-50 CrossRefGoogle Scholar
  35. Sit ST, Manser E (2011) Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci 124(Pt 5):679–683.  https://doi.org/10.1242/jcs.064964 CrossRefGoogle Scholar
  36. Small DH, Mok SS, Bornstein JC (2001) Alzheimer’s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2(8):595–598.  https://doi.org/10.1038/35086072 CrossRefGoogle Scholar
  37. Solito E, Sastre M (2012) Microglia function in Alzheimer’s disease. Front Pharmacol 3:14.  https://doi.org/10.3389/fphar.2012.00014 CrossRefGoogle Scholar
  38. Tsushima H, Emanuele M, Polenghi A, Esposito A, Vassalli M, Barberis A, Difato F, Chieregatti E (2015) HDAC6 and RhoA are novel players in Abeta-driven disruption of neuronal polarity. Nat Commun 6:7781.  https://doi.org/10.1038/ncomms8781 CrossRefGoogle Scholar
  39. van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L, Gerritsen W, Kooi EJ, Witte ME, Geurts JJ, de Vries HE, Peferoen-Baert R, van den Elsen PJ, van der Valk P, Amor S (2012) Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation. J Neuroinflamm 9:156.  https://doi.org/10.1186/1742-2094-9-156 Google Scholar
  40. Venneti S, Wiley CA, Kofler J (2009) Imaging microglial activation during neuroinflammation and Alzheimer’s disease. J Neuroimmune Pharmacol 4(2):227–243.  https://doi.org/10.1007/s11481-008-9142-2 CrossRefGoogle Scholar
  41. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol 36:74–81.  https://doi.org/10.1016/j.conb.2015.10.004 CrossRefGoogle Scholar
  42. Wolf SA, Boddeke HW, Kettenmann H (2017) Microglia in physiology and disease. Annu Rev Physiol 79:619–643.  https://doi.org/10.1146/annurev-physiol-022516-034406 CrossRefGoogle Scholar
  43. Xu Y, Wang D, Luo Y, Li W, Shan Y, Tan X, Zhu C (2015) Beta amyloid-induced upregulation of death receptor 6 accelerates the toxic effect of N-terminal fragment of amyloid precursor protein. Neurobiol Aging 36(1):157–168.  https://doi.org/10.1016/j.neurobiolaging.2014.07.027 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Translational Neuroscience, Jing’an District Centre Hospital of Shanghai, State Key Laboratory of Medical Neurobiology & Institutes of Brain ScienceFudan UniversityShanghaiChina

Personalised recommendations